Australia doesn’t often feature in the global neurotechnology spotlight — but last week week, it earned a front-row seat.
Synchron, the Australian-founded brain-computer interface (BCI) company now based in New York, on Friday announced it has secured US$200 million (A$308 million) through a Series D capital raise, including A$54 million from Australia’s National Reconstruction Fund Corporation (NRF). It’s one of the largest private rounds ever completed in the neurotech space and makes Synchron the first BCI company backed by the federal government’s flagship investment vehicle.
For an emerging sector defined by long development timelines, complex regulation and heavy R&D spend, late-stage capital of this scale is rare. For Australia, the participation is strategic: it signals a desire not just to fund research, but to anchor commercial activity and high-value manufacturing domestically.
What Synchron is building
Synchron’s implant, the Stentrode, is a tiny electrode array delivered via a catheter through the jugular vein and positioned next to the motor cortex. Rather than surgically opening the skull, the device is inserted through the vascular system — similar to placing a heart stent.
The implant records neural activity linked to movement intention, allowing users with paralysis from conditions like motor neurone disease (ALS/MND) or spinal cord injury to operate digital interfaces using thought-driven cursor control. Participants in early US trials have been able to text, email and browse the web.
Synchron’s key differentiator is its minimally invasive delivery method. Where other BCI developers rely on direct brain surgery, Synchron’s catheter-based approach may reduce surgical risk, widen patient eligibility and shorten regulatory pathways. It already has patients implanted in the United States under an FDA Investigational Device Exemption — a milestone only a handful of BCI companies have reached.
Inside the raise
The Series D round was led by a syndicate of US life-science and deep-tech investors. Synchron has not disclosed its valuation, but industry reporting suggests the round pushes the company towards “unicorn” status.
The NRF’s A$54 million equity stake makes Synchron the first neurotech company backed by the government’s new strategic investment fund. The NRF’s mandate is to build domestic industrial capability in priority areas such as medical manufacturing and advanced technologies.
Synchron says the funding will support its transition from early clinical work towards commercial readiness, including advancing towards a pivotal clinical trial and expanding manufacturing capacity. The company has also flagged continued investment in technical and engineering capability, as it works on future versions of its implant system.
A shifting competitive landscape
Interest in BCIs has accelerated over the past two years, driven by advances in machine learning and the miniaturisation of implantable hardware. Private investment has surged, and while brain interfaces have existed in research settings for decades, they are now edging towards practical use cases.
Neuralink has dominated public attention, thanks largely to the Elon Musk association and an approach involving surgical implantation via a robotic system. Synchron offers a contrasting philosophy: accessibility and scale over surgical complexity.
From a commercial standpoint, the less-invasive approach could become the differentiator. Implanting a device via a catheter is already routine in modern medicine; open-brain surgery is not.
Why Australia’s involvement matters
Australia produces world-class medical research, but many promising companies relocate offshore once serious funding is required. Synchron’s backing suggests a shift: the NRF wants Australia to participate in the commercial upside, not just early-stage discovery.
Building up future operations in Australia also brings benefits beyond capital deployment — including high-value local jobs in neuroscience, robotics, machine learning and advanced manufacturing.
It also gives Australia a direct stake in a technology that could define a new interface category: digital communication without physical movement.
“We founded Synchron in Australia with the belief that restoring independence to people living with severe motor impairment would require both bold science and practical engineering,” Synchron founder and CEO Tom Oxley said.
“NRFC’s investment is a validation of that vision and of the pioneering Australian innovation that underpins our technology,” he added.
“This support will help us move through our final clinical trials, advance toward US regulatory approval and establish a strong commercial hub in Australia. Most importantly, it brings us closer to delivering life-changing brain-computer interface devices to millions of people worldwide who are waiting for a solution.”
The bottom line
Synchron’s funding round marks a pivotal moment for the BCI field and a strategic win for Australia. With capital secured, the company now moves from proving the technology to preparing it for market.
If the pivotal trial succeeds, the first widely available brain-computer interface may not emerge from a neurosurgical theatre — but through a blood vessel. And part of that future may be built in Australia.